ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 254 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $291,136 | -69.9% | 10,835 | -71.5% | 0.00% | -66.7% |
| Q1 2023 | $965,835 | -39.2% | 38,025 | -2.9% | 0.00% | -50.0% |
| Q4 2022 | $1,588,127 | +694.1% | 39,155 | +801.8% | 0.01% | +500.0% |
| Q1 2022 | $200,000 | -89.6% | 4,342 | -82.6% | 0.00% | -87.5% |
| Q4 2020 | $1,916,000 | +75.8% | 24,971 | -1.4% | 0.01% | +100.0% |
| Q3 2020 | $1,090,000 | -83.4% | 25,319 | -83.4% | 0.00% | -87.9% |
| Q2 2020 | $6,583,000 | +297.8% | 152,418 | +165.0% | 0.03% | +200.0% |
| Q1 2020 | $1,655,000 | -87.4% | 57,514 | -72.3% | 0.01% | -74.4% |
| Q4 2019 | $13,171,000 | +293.0% | 207,649 | +74.6% | 0.04% | +258.3% |
| Q3 2019 | $3,351,000 | +524.0% | 118,924 | +487.2% | 0.01% | +500.0% |
| Q2 2019 | $537,000 | +66.8% | 20,254 | +20.7% | 0.00% | +100.0% |
| Q3 2018 | $322,000 | +107.7% | 16,785 | +47.5% | 0.00% | 0.0% |
| Q2 2018 | $155,000 | – | 11,377 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |